Icahn School of Medicine at Mount Sinai has been working with Intel to use Trusted Analytics Platform to leverage data science, graph analytics, and machine learning for faster discovery of new drug therapies.
Big data holds the promise to transform industries and research, and spawn new solutions to a range of challenges in healthcare and the life sciences. Yet, achieving the anticipated data insights remains elusive. Intel and the Icahn School of Medicine at Mount Sinai have initiated a project called DrugGraph to explore the applicability of data science advances to therapeutic drug discovery, using data science capabilities found in the open source project Trusted Analytics Platform to greatly reduce the complexity of big data analytics.
Icahn School of Medicine at Mount Sinai (ISMMS), in New York City, is a leader in medical and scientific training and education, biomedical research and patient care. ISMMS has a reputation for innovation and thoughtful risk taking and is ranked in the top 20 medical schools in America by US News and World Report.
Download complete Case Study (PDF)Download
Download